dc.contributor.authorNing, Xiaoyu
dc.date.accessioned2018-05-31T08:27:58Z
dc.date.available2018-05-31T08:27:58Z
dc.date.issued2018
dc.identifier.urihttp://hdl.handle.net/10356/75483
dc.description.abstractHundreds of skin diseases such like acne, contact dermatitis, rosacea, keloid and skin cancer have plagued human lives physically and psychologically. Mainly caused by genetic or extrinsic factors, skin diseases vary in symptoms and severity greatly - some can be temporary and minor while some can be permanent and life-threatening. One particular example is keloid - a pathological condition caused by over-exuberant fibroblast proliferation after skin injury. In this condition, lesions grow beyond the wound and do not regress over time. This leads to pain, pruritus, contractures and might even progress into skin cancer Current diagnosis of keloid, including clinical visualization, biopsy and spectroscopy; routinely only detect late stage keloid when abundant ECM has already been deposited under the scar. Moreover, such poor diagnosis and understanding of the underlying mechanism is coupled with complex multistage therapy, which pales in patient treatment effectiveness. Precise, early stage diagnosis of skin diseases such as keloid is a critical step to effective treatment. This involves detecting a target biomarker (e.g. CTGF, FAP-), that is upregulated in disease cells as compared to normal dermal fibroblasts. The development of probes that can specifically target and quantify the biomarker would allow the early diagnosis of keloid for the timely treatment and the monitoring of the response of the scars towards the treatment. Unfortunately, there are lack of such technologies and efforts in the field. This project aims to address this unmet need by characterize a type of transdermal molecular sensors that provide quantitative fluorescence signal based on the concentration of biomarkers. Specifically, for early diagnosis and monitoring of keloid development, a molecular probe is to be designed to detect keloid fibroblast. The potential biomarker that can activate the proposed probe is fibroblast activation protein alpha (FAP-) that is overexpressed in keloid fibroblast comparing to normal fibroblast.en_US
dc.format.extent48 p.en_US
dc.language.isoenen_US
dc.rightsNanyang Technological University
dc.subjectDRNTU::Engineering::Bioengineeringen_US
dc.titleNovel probe for precise diagnosis of pathological scarsen_US
dc.typeFinal Year Project (FYP)en_US
dc.contributor.supervisorXu Chenjieen_US
dc.contributor.schoolSchool of Chemical and Biomedical Engineeringen_US
dc.description.degreeBachelor of Engineering (Chemical and Biomolecular Engineering)en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record